Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Lin, Jun ^a   Zhang, Qiang ^b   Lu, Yi ^a   Xue, Wenrui ^b   Xu, Yue ^b   Zhu, Yichen ^a   Hu, Xiaopeng ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; MESSENGER RNA; PHOSPHATASE; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN PHOSPHATASE 2C; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER TISSUE; CELL VIABILITY; CELL VIABILITY ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN-SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84901379395     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098418     Document Type: Article

References (33)

1. Cohen SM, Shirai T, Steineck G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl: 105-115. (Pubitemid 32056470)
2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, et al. (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234-241.
3. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, et al. (2014) EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. Eur Urol 65: 778-792.
4. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, et al. (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34. (Pubitemid 43049607)
5. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, et al. (1995) The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 154: 2059-2063; discussion 2063-2054.
6. Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D (2012) RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest 122: 1503-1518.
7. Chang JS, Lara PN Jr, Pan CX (2012) Progress in personalizing chemotherapy for bladder cancer. Adv Urol 2012: 364919.
8. Wei G, Ku S, Ma GK, Saito S, Tang AA, et al. (2007) HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A 104: 13040-13045. (Pubitemid 351737589)
9. D'Orazi G, Rinaldo C, Soddu S (2012) Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res 31: 63.
10. Hofmann TG, Glas C, Bitomsky N (2013) HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays 35: 55-64.
11. Puca R, Nardinocchi L, Givol D, D'Orazi G (2010) Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 29: 4378-4387.
12. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, et al. (2002) Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
13. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, et al. (2008) Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10: 812-824. (Pubitemid 351927710)
14. Puca R, Nardinocchi L, Pistritto G, D'Orazi G (2008) Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 109: 403-410.
15. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, et al. (2002) Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4: 1-10. (Pubitemid 34071974)
16. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, et al. (2007) MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 25: 739-750. (Pubitemid 46341925)
17. Lazzari C, Prodosmo A, Siepi F, Rinaldo C, Galli F, et al. (2011) HIPK2 phosphorylates DeltaNp63alpha and promotes its degradation in response to DNA damage. Oncogene 30: 4802-4813.
18. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, et al. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19: 6517-6526.
19. Song JY, Ryu SH, Cho YM, Kim YS, Lee BM, et al. (2013) Wip1 suppresses apoptotic cell death through direct dephosphorylation of BAX in response to gamma-radiation. Cell Death Dis 4: e744.
20. Choi DW, Na W, Kabir MH, Yi E, Kwon S, et al. (2013) WIP1, a homeostatic regulator of the DNA damage response, is targeted by HIPK2 for phosphorylation and degradation. Mol Cell 51: 374-385.
21. Wang L, Mosel AJ, Oakley GG, Peng A (2012) Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol Cancer Ther 11: 2401-2409.
22. Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, et al. (2012) Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci U S A 109: E68-75.
23. Esaki T, Nakano S, Masumoto N, Fujishima H, Niho Y (1996) Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 65: 479-484. (Pubitemid 26083256)
24. Xu N, Shen C, Luo Y, Xia L, Xue F, et al. (2012) Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 425: 468-472.
25. Wang F, Li X, Xie X, Zhao L, Chen W (2008) UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 582: 1919-1927.
26. Yang C, Li X, Wang Y, Zhao L, Chen W (2012) Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 496: 8-16.
27. Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, et al. (2013) WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene 32: 375-387.
28. Juffs HG, Moore MJ, Tannock IF (2002) The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 3: 738-747. (Pubitemid 35446743)
29. Gupta S, Mahipal A (2013) Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Control 20: 200-210.
30. Kamat AM, Sethi G, Aggarwal BB (2007) Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6: 1022-1030. (Pubitemid 46554572)
31. Chung J, Kwak C, Jin RJ, Lee CH, Lee KH, et al. (2004) Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro. Cancer Lett 203: 155-161. (Pubitemid 38058683)
32. Krieghoff-Henning E, Hofmann TG (2008) HIPK2 and cancer cell resistance to therapy. Future Oncol 4: 751-754.
33. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, et al. (2008) The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27: 123-135.